14 Stocks Moving In Wednesday’s After-Hours Session
Gainers
Moderna (NASDAQ: MRNA) shares are trading higher after the company reported initial booster data against SARS-CoV-2 variants of concern.
Doctor Offers A Chance To Win A Tesla After COVID-19 Vaccination
While some people are scrambling to get the COVID-19 vaccine, some are hesitating for various reasons. But a family physician in Buffalo, New York, is doing his best to get as many people vaccinated as possible — even offering up a chance at winning a Tesla Inc (NASDAQ: TSLA) Model 3.
‘White House plans to redistribute unordered vaccine supply, telling states: Use it or lose it’ -Washington Post
https://www.washingtonpost.com/health/2021/05/04/vaccine-distribution-biden/
Pfizer COVID-19 Vaccine Expected To Get FDA Emergency Approval For Age Group 12-15 Next Week
The Food and Drug Administration has plans to authorize the emergency use of Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) jointly-developed COVID-19 vaccine in adolescents aged between 12 to 15 years, t
Is Now The Time To Buy Stock In Vaxart Or Moderna?
One of the most common questions traders have about stocks is “Why Is It Moving?”
That’s why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro. WIIMs are a one-sentence description as to why that stock is moving.
Here’s the latest news and updates for Vaxart and Moderna.
Moderna Inks Supply Pact Of 500M COVID-19 Vaccine Doses To COVAX Effort Starting Q4
Moderna Inc (NASDAQ: MRNA) has announced an agreement with vaccine promoter Gavi to supply up to 500 million doses of its COVID-19…
Who Is — And Will Be — Making Money From COVID-19 Vaccines?
Schroders' Expert John Bowler Analyzes The Pharmaceutical Groups Involved In COVID-19 Drug Development, Emphasizing That Their Efforts Will Be Rewarded In The Future, Despite Current Low Benefits.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.